Evidence map›Paper›PMID 29474374›Full record

ArticlePloS one2018

Neither Lys- and DAP-type peptidoglycans stimulate mouse or human innate immune cells via Toll-like receptor 2.

Marybeth Langer, Alanson W Girton, Narcis I Popescu, Tarea Burgett, Jordan P Metcalf, K Mark Coggeshall

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marybeth LangerThe Oklahoma Medical Research Foundation, Program in Arthritis & Immunology, Oklahoma City, OK, United States of America.
Alanson W GirtonThe Oklahoma Medical Research Foundation, Program in Arthritis & Immunology, Oklahoma City, OK, United States of America.
Narcis I PopescuThe Oklahoma Medical Research Foundation, Program in Arthritis & Immunology, Oklahoma City, OK, United States of America.
Tarea BurgettThe Oklahoma Medical Research Foundation, Program in Arthritis & Immunology, Oklahoma City, OK, United States of America.
Jordan P MetcalfThe Department of Medicine, Pulmonary and Critical Care Div., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.
K Mark CoggeshallThe Oklahoma Medical Research Foundation, Program in Arthritis & Immunology, Oklahoma City, OK, United States of America.ORCID 0000-0003-4797-9095
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
Development of a mouse model of peptidoglycan-induced pathologyR21AI113020 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK, LUPU, FLOREA · 2014 to 2015
$471k
Antiviral Immunosuppression by Cigarette SmokeI01BX001937 · VA · OKLAHOMA CITY VA MEDICAL CENTER · PI METCALF, JORDAN PATRICK · 2015 to 2019
–
BLRD VA I01 BX001937NIAID NIH HHS R21 AI113020NIAID NIH HHS U19 AI062629
6 · The paper itself

Abstract

Peptidoglycan (PGN), a major component of bacterial cell walls, is a pathogen-associated molecular pattern (PAMP) that causes innate immune cells to produce inflammatory cytokines that escalate the host response during infection. In order to better understand the role of PGN in infection, we wanted to gain insight into the cellular receptor for PGN. Although the receptor was initially identified as Toll-like receptor 2 (TLR2), this receptor has remained controversial and other PGN receptors have been reported. We produced PGN from live cultures of Bacillus anthracis and Staphylococcus aureus and tested samples of PGN isolated during the purification process to determine at what point TLR2 activity was removed, if at all. Our results indicate that although live B. anthracis and S. aureus express abundant TLR2 ligands, highly-purified PGN from either bacterial source is not recognized by TLR2.

Indexed as

AnimalsBacillus anthracisFemaleHumansImmunity, InnateMaleMiceMice, Mutant StrainsPeptidoglycanStaphylococcus aureusToll-Like Receptor 2PeptidoglycanTLR2 protein, humanTlr2 protein, mouseToll-Like Receptor 2

Identifiers

PMID29474374
PMCPMC5825070
OpenAlexW2793472432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.